<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37225921</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-507X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature reviews. Nephrology</Title><ISOAbbreviation>Nat Rev Nephrol</ISOAbbreviation></Journal><ArticleTitle>Pathogenic cellular and molecular mediators in lupus nephritis.</ArticleTitle><Pagination><StartPage>491</StartPage><EndPage>508</EndPage><MedlinePgn>491-508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41581-023-00722-z</ELocationID><Abstract><AbstractText>Kidney involvement in patients with systemic lupus erythematosus - lupus nephritis (LN) - is one of the most important and common clinical manifestations of this disease and occurs in 40-60% of patients. Current treatment regimens achieve a complete kidney response in only a minority of affected individuals, and 10-15% of patients with LN develop kidney failure, with its attendant morbidity and considerable prognostic implications. Moreover, the medications most often used to treat LN - corticosteroids in combination with immunosuppressive or cytotoxic drugs - are associated with substantial side effects. Advances in proteomics, flow cytometry and RNA sequencing have led to important new insights into immune cells, molecules and mechanistic pathways that are instrumental in the pathogenesis of LN. These insights, together with a renewed focus on the study of human LN kidney tissue, suggest new therapeutic targets that are already being tested in lupus animal models and early-phase clinical trials and, as such, are hoped to eventually lead to meaningful improvements in the care of patients with systemic lupus erythematosus-associated kidney disease.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Chandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Houston, Houston, TX, USA. cmohan@central.uh.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putterman</LastName><ForeName>Chaim</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3204-6068</Identifier><AffiliationInfo><Affiliation>Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. chaim.putterman@biu.ac.il.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology and Department of Microbiology &amp; Immunology, Albert Einstein College of Medicine, Bronx, NY, USA. chaim.putterman@biu.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Nephrol</MedlineTA><NlmUniqueID>101500081</NlmUniqueID><ISSNLinking>1759-5061</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37225921</ArticleId><ArticleId IdType="doi">10.1038/s41581-023-00722-z</ArticleId><ArticleId IdType="pii">10.1038/s41581-023-00722-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parikh, S. V., Almaani, S., Brodsky, S. &amp; Rovin, B. H. Update on lupus nephritis: core curriculum 2020. Am. J. Kidney Dis. 76, 265&#x2013;281 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32220510</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocaoglu, M. et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades &#x2014; The Lupus Midwest Network (LUMEN). Arthritis Rheumatol. 75, 567&#x2013;573 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42375</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson, A. What is damaging the kidney in lupus nephritis? Nat. Rev. Rheumatol. 12, 143&#x2013;153 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26581344</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2015.159</ArticleId></ArticleIdList></Reference><Reference><Citation>Lech, M. &amp; Anders, H. J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol. 24, 1357&#x2013;1366 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23929771</ArticleId><ArticleId IdType="pmc">3752952</ArticleId><ArticleId IdType="doi">10.1681/ASN.2013010026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan, C. &amp; Putterman, C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat. Rev. Nephrol. 11, 329&#x2013;341 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25825084</ArticleId><ArticleId IdType="doi">10.1038/nrneph.2015.33</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, R. D., Dimou, P., Northey, S. J. &amp; Beresford, M. W. Mesangial cells are key contributors to the fibrotic damage seen in the lupus nephritis glomerulus. J. Inflamm. 16, 22 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-019-0227-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitching, A. R. &amp; Hickey, M. J. Immune cell behaviour and dynamics in the kidney &#x2014; insights from in vivo imaging. Nat. Rev. Nephrol. 18, 22&#x2013;37 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34556836</ArticleId><ArticleId IdType="doi">10.1038/s41581-021-00481-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902&#x2013;914 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31209404</ArticleId><ArticleId IdType="pmc">6726437</ArticleId><ArticleId IdType="doi">10.1038/s41590-019-0398-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Der, E. et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat. Immunol. 20, 915&#x2013;927 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31110316</ArticleId><ArticleId IdType="pmc">6584054</ArticleId><ArticleId IdType="doi">10.1038/s41590-019-0386-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava, A. et al. Integrated urine proteomics and renal single-cell genomics identify an IFN-&#x3b3; response gradient in lupus nephritis. JCI Insight 5, e138345 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32396533</ArticleId><ArticleId IdType="pmc">7406291</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.138345</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Z. et al. A single-cell survey of the human glomerulonephritis. J. Cell Mol. Med. 25, 4684&#x2013;4695 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33754492</ArticleId><ArticleId IdType="pmc">8107090</ArticleId><ArticleId IdType="doi">10.1111/jcmm.16407</ArticleId></ArticleIdList></Reference><Reference><Citation>Der, E. et al. Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight 2, e93009 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28469080</ArticleId><ArticleId IdType="pmc">5414553</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.93009</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanarsa, K. et al. Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. Ann. Rheum. Dis. 79, 1349&#x2013;1361 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32651195</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2019-216312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley, S. et al. Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nat. Commun. 11, 2197 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32366845</ArticleId><ArticleId IdType="pmc">7198599</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-15986-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley, S. et al. Identification of low-abundance urinary biomarkers in lupus nephritis using electrochemiluminescence immunoassays. Arthritis Rheumatol. 71, 744&#x2013;755 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30618193</ArticleId><ArticleId IdType="doi">10.1002/art.40813</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava, A. et al. Urine proteomics and renal single&#x2010;cell transcriptomics implicate interleukin&#x2010;16 in lupus nephritis. Arthritis Rheumatol. 74, 829&#x2013;839 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34783463</ArticleId><ArticleId IdType="pmc">9050800</ArticleId><ArticleId IdType="doi">10.1002/art.42023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolo, M. et al. Deep phenotyping of urinary leukocytes by mass cytometry reveals a leukocyte signature for early and non-invasive prediction of response to treatment in active lupus nephritis. Front. Immunol. 11, 256 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32265898</ArticleId><ArticleId IdType="pmc">7105605</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.00256</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhingra, S., Qureshi, R., Abdellatif, A., Gaber, L. W. &amp; Truong, L. D. Tubulointerstitial nephritis in systemic lupus erythematosus: innocent bystander or ominous presage. Histol. Histopathol. 29, 553&#x2013;565 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24288339</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark, M. R., Trotter, K. &amp; Chang, A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin. Nephrol. 35, 455&#x2013;464 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26573548</ArticleId><ArticleId IdType="pmc">4653081</ArticleId><ArticleId IdType="doi">10.1016/j.semnephrol.2015.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Obri&#x219;c&#x103; B, J. R. et al. Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions. Lupus 27, 1455&#x2013;1463 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29759047</ArticleId><ArticleId IdType="doi">10.1177/0961203318776109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilstra, J. S. et al. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J. Clin. Invest. 128, 4884&#x2013;4897 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30130253</ArticleId><ArticleId IdType="pmc">6205402</ArticleId><ArticleId IdType="doi">10.1172/JCI120859</ArticleId></ArticleIdList></Reference><Reference><Citation>Winchester, R. et al. Immunologic characteristics of intrarenal T cells: trafficking of expanded CD8<sup>+</sup> T cell &#x3b2;-chain clonotypes in progressive lupus nephritis. Arthritis Rheum. 64, 1589&#x2013;1600 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22130908</ArticleId><ArticleId IdType="pmc">3297718</ArticleId><ArticleId IdType="doi">10.1002/art.33488</ArticleId></ArticleIdList></Reference><Reference><Citation>Linke, A., Tiegs, G. &amp; Neumann, K. Pathogenic T-cell responses in immune-mediated glomerulonephritis. Cells 11, 1625 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35626662</ArticleId><ArticleId IdType="pmc">9139939</ArticleId><ArticleId IdType="doi">10.3390/cells11101625</ArticleId></ArticleIdList></Reference><Reference><Citation>Smita, S., Chikina, M., Shlomchik, M. J. &amp; Tilstra, J. S. Heterogeneity and clonality of kidney-infiltrating T cells in murine lupus nephritis. JCI Insight 7, e156048 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35271505</ArticleId><ArticleId IdType="pmc">9089785</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.156048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, P. M. &amp; Tsokos, G. C. The role of CD8<sup>+</sup> T-cell systemic lupus erythematosus pathogenesis: an update. Curr. Opin. Rheumatol. 33, 586&#x2013;591 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34183542</ArticleId><ArticleId IdType="pmc">8567317</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000815</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzi, L. et al. Predominance of CD8<sup>+</sup> T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis Rheum. 56, 2362&#x2013;2370 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17599764</ArticleId><ArticleId IdType="doi">10.1002/art.22654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, T. et al. Association between tubulointerstitial CD8<sup>+</sup> T cells and renal prognosis in lupus nephritis. Int. Immunopharmacol. 99, 107877 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34217995</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2021.107877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiechmann, A. et al. CD107a<sup>+</sup> (LAMP-1) cytotoxic CD8<sup>+</sup> T-cells in lupus nephritis patients. Front. Med. 8, 556776 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.556776</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, L. et al. Targeting tissue-resident memory CD8<sup>+</sup> T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis. Mol. Ther. 30, 2746&#x2013;2759 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35514086</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2022.04.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, M. et al. JAK/STAT signaling controls the fate of CD8<sup>+</sup>CD103<sup>+</sup> tissue-resident memory T cell in lupus nephritis. J. Autoimmun. 109, 102424 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32085893</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2020.102424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong, H. et al. TGF-beta-Induced CD8<sup>+</sup>CD103<sup>+</sup> regulatory T cells show potent therapeutic effect on chronic graft-versus-host disease lupus by suppressing B cells. Front. Immunol. 9, 35 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29441062</ArticleId><ArticleId IdType="pmc">5797539</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.00035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H., Lan, L., Chen, J., Xiao, L. &amp; Han, F. Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients. Lupus Sci. Med 9, e000717 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35973743</ArticleId><ArticleId IdType="pmc">9386235</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000717</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto, A., Fujio, K., Tsuno, N. H., Takahashi, K. &amp; Yamamoto, K. Kidney-infiltrating CD4<sup>+</sup> T-cell clones promote nephritis in lupus-prone mice. Kidney Int. 82, 969&#x2013;979 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22763816</ArticleId><ArticleId IdType="doi">10.1038/ki.2012.242</ArticleId></ArticleIdList></Reference><Reference><Citation>Masutani, K. et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 44, 2097&#x2013;2106 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11592372</ArticleId><ArticleId IdType="doi">10.1002/1529-0131(200109)44:9&lt;2097::AID-ART360&gt;3.0.CO;2-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesquita, D. Jr et al. CD4<sup>+</sup> T helper cells and regulatory T cells in active lupus nephritis: an imbalance towards a predominant Th1 response? Clin. Exp. Immunol. 191, 50&#x2013;59 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28945272</ArticleId><ArticleId IdType="doi">10.1111/cei.13050</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhfakh, R. et al. Th17 and Th1 cells in systemic lupus erythematosus with focus on lupus nephritis. Immunol. Res. 70, 644&#x2013;653 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35666434</ArticleId><ArticleId IdType="doi">10.1007/s12026-022-09296-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquissi, F. C. &amp; Abensur, H. The Th17/IL-17 Axis and kidney diseases, with focus on lupus nephritis. Front. Med. 8, 654912 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.654912</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, D. Y. et al. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 21, 1385&#x2013;1396 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22892208</ArticleId><ArticleId IdType="doi">10.1177/0961203312457718</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy, S. et al. Effect of induction therapy on circulating T-helper 17 and T-regulatory cells in active proliferative lupus nephritis. Int. J. Rheum. Dis. 21, 1040&#x2013;1048 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29392921</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.13272</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga, T., Ichinose, K. &amp; Tsokos, G. C. T cells and IL-17 in lupus nephritis. Clin. Immunol. 185, 95&#x2013;99 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27109641</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2016.04.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisitkun, P. et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 37, 1104&#x2013;1115 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23123062</ArticleId><ArticleId IdType="pmc">3594848</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2012.08.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, T. et al. Function of the Th17/interleukin-17A immune response in murine lupus nephritis. Arthritis Rheumatol. 67, 475&#x2013;487 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25385550</ArticleId><ArticleId IdType="doi">10.1002/art.38955</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y., Tang, D., Yin, L. &amp; Dai, Y. New insights for regulatory T cell in lupus nephritis. Autoimmun. Rev. 21, 103134 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35690245</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2022.103134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose, A. et al. IL-2 Therapy diminishes renal inflammation and the activity of kidney-infiltrating CD4<sup>+</sup> T cells in murine lupus nephritis. Cells 8, 1234 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31614462</ArticleId><ArticleId IdType="pmc">6829607</ArticleId><ArticleId IdType="doi">10.3390/cells8101234</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, J. H. et al. Mouse IL-2/CD25 fusion protein induces regulatory T cell expansion and immune suppression in preclinical models of systemic lupus erythematosus. J. Immunol. 207, 34&#x2013;43 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34108258</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2100078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, J. J. et al. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells. Kidney Int. 91, 603&#x2013;615 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27914701</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2016.09.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadei, C. et al. Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI Insight 5, e127428 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31013255</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.127428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gensous, N., Schmitt, N., Richez, C., Ueno, H. &amp; Blanco, P. T follicular helper cells, interleukin-21 and systemic lupus erythematosus. Rheumatology 56, 516&#x2013;523 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27498357</ArticleId></ArticleIdList></Reference><Reference><Citation>Liarski, V. M. et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci. Transl. Med. 6, 230ra246 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3008146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitrin, J. et al. The Ox40/Ox40 ligand pathway promotes pathogenic Th cell responses, plasmablast accumulation, and lupus nephritis in NZB/W F1 mice. J. Immunol. 199, 1238&#x2013;1249 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28696253</ArticleId><ArticleId IdType="pmc">5544932</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1700608</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortini, A. et al. B cell OX40L supports T follicular helper cell development and contributes to SLE pathogenesis. Ann. Rheum. Dis. 76, 2095&#x2013;2103 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28818832</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-211499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mountz, J. D., Hsu, H. C. &amp; Ballesteros-Tato, A. Dysregulation of T follicular helper cells in lupus. J. Immunol. 202, 1649&#x2013;1658 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30833421</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1801150</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, L. E. et al. Circulating CXCR5<sup>+</sup>CD4<sup>+</sup> helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. Lupus 24, 909&#x2013;917 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25654980</ArticleId><ArticleId IdType="doi">10.1177/0961203314567750</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, J. Y. et al. Disruption of pathogenic cellular networks by IL-21 blockade leads to disease amelioration in murine lupus. J. Immunol. 198, 2578&#x2013;2588 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28219887</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1601687</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao, M. et al. Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res. Ther. 23, 167 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34116715</ArticleId><ArticleId IdType="pmc">8194162</ArticleId><ArticleId IdType="doi">10.1186/s13075-021-02535-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, B. et al. The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin. Immunol. 183, 46&#x2013;53 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28709914</ArticleId><ArticleId IdType="pmc">5673570</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2017.07.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, P. et al. Restoration of follicular T regulatory/helper cell balance by OX40L-JAG1 cotreatment suppresses lupus nephritis in NZBWF1/j mice. J. Immunol. 208, 2467&#x2013;2481 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35470257</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2200057</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, K. et al. Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus. Clin. Transl. Immunol. 10, e1293 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1293</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsova, K. et al. B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J. Clin. Invest. 127, 1392&#x2013;1404 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28240602</ArticleId><ArticleId IdType="pmc">5373868</ArticleId><ArticleId IdType="doi">10.1172/JCI91250</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. T-bet<sup>+</sup>CD11c<sup>+</sup> B cells are critical for antichromatin immunoglobulin G production in the development of lupus. Arthritis Res. Ther. 19, 225 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28982388</ArticleId><ArticleId IdType="pmc">5629756</ArticleId><ArticleId IdType="doi">10.1186/s13075-017-1438-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c<sup>hi</sup>T-bet<sup>+</sup> B cells in SLE. Nat. Commun. 9, 1758 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29717110</ArticleId><ArticleId IdType="pmc">5931508</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-03750-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramskold, D. et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine 40, 517&#x2013;527 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30593436</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2018.12.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W. et al. Excessive CD11c<sup>+</sup>Tbet<sup>+</sup> B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus. Proc. Natl Acad. Sci. USA 116, 18550&#x2013;18560 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31451659</ArticleId><ArticleId IdType="pmc">6744857</ArticleId><ArticleId IdType="doi">10.1073/pnas.1901340116</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, S. W., Arkatkar, T., Jacobs, H. M., Rawlings, D. J. &amp; Jackson, S. W. Generation of functional murine CD11c<sup>+</sup> age-associated B cells in the absence of B cell T-bet expression. Eur. J. Immunol. 49, 170&#x2013;178 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30353919</ArticleId><ArticleId IdType="doi">10.1002/eji.201847641</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnell, J. L. et al. Role of CD11c<sup>+</sup> T-bet<sup>+</sup> B cells in human health and disease. Cell Immunol. 321, 40&#x2013;45 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28756897</ArticleId><ArticleId IdType="doi">10.1016/j.cellimm.2017.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>You, X. et al. Double negative B cell is associated with renal impairment in systemic lupus erythematosus and acts as a marker for nephritis remission. Front. Med. 7, 85 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00085</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeli, M. et al. Local renal autoantibody production in lupus nephritis. J. Am. Soc. Nephrol. 22, 296&#x2013;305 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21088295</ArticleId><ArticleId IdType="pmc">3029902</ArticleId><ArticleId IdType="doi">10.1681/ASN.2010050515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinloch, A. J. et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 66, 3359&#x2013;3370 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25306868</ArticleId><ArticleId IdType="pmc">4264660</ArticleId><ArticleId IdType="doi">10.1002/art.38888</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham, R. et al. Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis. J. Clin. Invest 132, e155350 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35608910</ArticleId><ArticleId IdType="pmc">9246394</ArticleId><ArticleId IdType="doi">10.1172/JCI155350</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, M., Gnirck, A. C. &amp; Turner, J. E. Innate lymphoid cells in renal inflammation. Front. Immunol. 11, 72 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32063905</ArticleId><ArticleId IdType="pmc">7000421</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.00072</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, Y. W. et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum. 60, 1753&#x2013;1763 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19479851</ArticleId><ArticleId IdType="doi">10.1002/art.24556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudspeth, K. et al. Natural killer cell expression of Ki67 is associated with elevated serum IL-15, disease activity and nephritis in systemic lupus erythematosus. Clin. Exp. Immunol. 196, 226&#x2013;236 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30693467</ArticleId><ArticleId IdType="pmc">6468178</ArticleId><ArticleId IdType="doi">10.1111/cei.13263</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffschick, A., Fuchs, S., Malmstrom, V., Gunnarsson, I. &amp; Brauner, H. Kidney infiltrating NK cells and NK-like T-cells in lupus nephritis: presence, localization, and the effect of immunosuppressive treatment. Clin. Exp. Immunol. 207, 199&#x2013;204 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35020891</ArticleId><ArticleId IdType="doi">10.1093/cei/uxab035</ArticleId></ArticleIdList></Reference><Reference><Citation>Spada, R. et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J. Leukoc. Biol. 97, 583&#x2013;598 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25583577</ArticleId><ArticleId IdType="pmc">5477896</ArticleId><ArticleId IdType="doi">10.1189/jlb.4A0714-326R</ArticleId></ArticleIdList></Reference><Reference><Citation>Duster, M. et al. T cell-derived IFN-&#x3b3; downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus. Eur. J. Immunol. 48, 1364&#x2013;1375 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29671873</ArticleId><ArticleId IdType="doi">10.1002/eji.201747303</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourde-Chiche, N. et al. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology 56, 477&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28031441</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551&#x2013;565 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27040498</ArticleId><ArticleId IdType="pmc">5426482</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi, H. &amp; Mayadas, T. N. Neutrophils in lupus nephritis. Curr. Opin. Rheumatol. 31, 193&#x2013;200 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30540580</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000577</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi, H. et al. Neutrophil Fc&#x3b3;RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. J. Clin. Invest. 127, 3810&#x2013;3826 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28891817</ArticleId><ArticleId IdType="pmc">5617671</ArticleId><ArticleId IdType="doi">10.1172/JCI94039</ArticleId></ArticleIdList></Reference><Reference><Citation>Skopelja-Gardner, S. et al. Acute skin exposure to ultraviolet light triggers neutrophil-mediated kidney inflammation. Proc. Natl Acad. Sci. USA 118, e2019097118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33397815</ArticleId><ArticleId IdType="pmc">7826360</ArticleId><ArticleId IdType="doi">10.1073/pnas.2019097118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fousert, E., Toes, R. &amp; Desai, J. Neutrophil extracellular traps (NETs) take the central stage in driving autoimmune responses. Cells 9, 915 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32276504</ArticleId><ArticleId IdType="pmc">7226846</ArticleId><ArticleId IdType="doi">10.3390/cells9040915</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden, M. et al. Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology 57, 1228&#x2013;1234 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29608758</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/key067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl Acad. Sci. USA 107, 9813&#x2013;9818 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20439745</ArticleId><ArticleId IdType="pmc">2906830</ArticleId><ArticleId IdType="doi">10.1073/pnas.0909927107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay, S. H., Celhar, T. &amp; Fairhurst, A. M. Low-density neutrophils in systemic lupus erythematosus. Arthritis Rheumatol. 72, 1587&#x2013;1595 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32524751</ArticleId><ArticleId IdType="pmc">7590095</ArticleId><ArticleId IdType="doi">10.1002/art.41395</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, S. et al. Neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus. J. Rheumatol. 47, 190875 (2019).</Citation></Reference><Reference><Citation>Frangou, E. et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann. Rheum. Dis. 78, 238&#x2013;248 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30563869</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-213181</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortner, K. A. et al. Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice. Lupus Sci. Med. 7, e000387 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32343673</ArticleId><ArticleId IdType="pmc">7199895</ArticleId><ArticleId IdType="doi">10.1136/lupus-2020-000387</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel, R. R. &amp; Kaplan, M. J. Deadliest catch: neutrophil extracellular traps in autoimmunity. Curr. Opin. Rheumatol. 32, 64&#x2013;70 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31644465</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000667</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538&#x2013;552 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21613614</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1100450</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell, A. M., Kashgarian, M. &amp; Shlomchik, M. J. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl. Med. 4, 157ra141 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23100627</ArticleId><ArticleId IdType="pmc">3704198</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3004801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienhofer, D. et al. Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps. JCI Insight 2, e92920 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28515366</ArticleId><ArticleId IdType="pmc">5436535</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.92920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, R. A. et al. Lupus and proliferative nephritis are PAD4 independent in murine models. JCI Insight 2, e92926 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28515361</ArticleId><ArticleId IdType="pmc">5436537</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.92926</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, R. A. et al. Murine lupus is neutrophil elastase-independent in the MRL.Faslpr model. PLoS One 15, e0226396 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32243431</ArticleId><ArticleId IdType="pmc">7122749</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0226396</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria, N. I. &amp; Davidson, A. Renal macrophages and dendritic cells in SLE nephritis. Curr. Rheumatol. Rep. 19, 81 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29119288</ArticleId><ArticleId IdType="doi">10.1007/s11926-017-0708-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysore, V. et al. Monocytes transition to macrophages within the inflamed vasculature via monocyte CCR2 and endothelial TNFR2. J. Exp. Med. 219, e20210562 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35404389</ArticleId><ArticleId IdType="pmc">9006314</ArticleId><ArticleId IdType="doi">10.1084/jem.20210562</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria, N. I. &amp; Davidson, A. Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat. Rev. Rheumatol. 16, 255&#x2013;267 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32203285</ArticleId><ArticleId IdType="doi">10.1038/s41584-020-0401-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu, R., Bethunaickan, R., Singh, S. &amp; Davidson, A. Structure and function of renal macrophages and dendritic cells from lupus-prone mice. Arthritis Rheumatol. 66, 1596&#x2013;1607 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24866269</ArticleId><ArticleId IdType="pmc">4547797</ArticleId><ArticleId IdType="doi">10.1002/art.38410</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatiades, E. G. et al. Immune monitoring of trans-endothelial transport by kidney-resident macrophages. Cell 166, 991&#x2013;1003 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27477514</ArticleId><ArticleId IdType="pmc">4983224</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.06.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Richoz, N. et al. Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. JCI Insight 7, e159751 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36345939</ArticleId><ArticleId IdType="pmc">9675473</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.159751</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera Garcia, A. et al. Infiltrating CD16<sup>+</sup> are associated with a reduction in peripheral CD14<sup>+</sup>CD16<sup>++</sup> monocytes and severe forms of lupus nephritis. Autoimmune Dis. 2016, 9324315 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">28070418</ArticleId><ArticleId IdType="pmc">5187455</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani, K. et al. Fractalkine expression and CD16<sup>+</sup> monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am. J. Physiol. Renal Physiol. 299, F207&#x2013;F216 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20410215</ArticleId><ArticleId IdType="doi">10.1152/ajprenal.00482.2009</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto, S. et al. Elevated levels of fractalkine expression and accumulation of CD16<sup>+</sup> monocytes in glomeruli of active lupus nephritis. Am. J. Kidney Dis. 50, 47&#x2013;58 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17591524</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2007.04.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Olaru, F. et al. Intracapillary immune complexes recruit and activate slan-expressing CD16<sup>+</sup> monocytes in human lupus nephritis. JCI Insight 3, e96492 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29875315</ArticleId><ArticleId IdType="pmc">6124405</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.96492</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson, A. Renal mononuclear phagocytes in lupus nephritis. ACR Open Rheumatol. 3, 442&#x2013;450 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34060247</ArticleId><ArticleId IdType="pmc">8280821</ArticleId><ArticleId IdType="doi">10.1002/acr2.11269</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer L, B. R. et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J. Immunol. 180, 1938&#x2013;1947 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18209092</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.180.3.1938</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethunaickan, R. et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J. Immunol. 186, 4994&#x2013;5003 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21411733</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1003010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriakose, J. et al. Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. J. Clin. Invest. 129, 2251&#x2013;2265 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31033479</ArticleId><ArticleId IdType="pmc">6546471</ArticleId><ArticleId IdType="doi">10.1172/JCI125116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias, C. B. et al. Role of renal expression of CD68 in the long-term prognosis of proliferative lupus nephritis. J. Nephrol. 30, 87&#x2013;94 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">26621103</ArticleId><ArticleId IdType="doi">10.1007/s40620-015-0252-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14&#x2013;20 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25035950</ArticleId><ArticleId IdType="pmc">4123412</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2014.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, P. M., Nikolic-Paterson, D. J. &amp; Lan, H. Y. Macrophages: versatile players in renal inflammation and fibrosis. Nat. Rev. Nephrol. 15, 144&#x2013;158 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30692665</ArticleId><ArticleId IdType="doi">10.1038/s41581-019-0110-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme, J. M. C. Macrophage subpopulations in systemic lupus erythematosus. Discov. Med. 13, 151&#x2013;158 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22369974</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata, Y. et al. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J. Immunol. 188, 4568&#x2013;4580 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22467656</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1102154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwant, L. E. et al. Macrophages in lupus nephritis: exploring a potential new therapeutic avenue. Autoimmun. Rev. 21, 103211 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36252930</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2022.103211</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmes, G. et al. CD163<sup>+</sup> M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res. Ther. 18, 90 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27091114</ArticleId><ArticleId IdType="pmc">4835936</ArticleId><ArticleId IdType="doi">10.1186/s13075-016-0989-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto, D. et al. Dysregulated heme oxygenase-1<sup>low</sup> M2-like macrophages augment lupus nephritis via Bach1 induced by type I interferons. Arthritis Res. Ther. 20, 64 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29636091</ArticleId><ArticleId IdType="pmc">5894134</ArticleId><ArticleId IdType="doi">10.1186/s13075-018-1568-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, T. et al. Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages. Front. Immunol. 11, 671 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32351512</ArticleId><ArticleId IdType="pmc">7174755</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.00671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet, J. M. et al. Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis. J. Am. Soc. Nephrol. 31, 1335&#x2013;1347 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32300067</ArticleId><ArticleId IdType="pmc">7269356</ArticleId><ArticleId IdType="doi">10.1681/ASN.2019121285</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia, S. et al. Renal fibrosis in lupus nephritis. Int J. Mol. Sci. 23, 14317 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36430794</ArticleId><ArticleId IdType="pmc">9699516</ArticleId><ArticleId IdType="doi">10.3390/ijms232214317</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers, S. A. et al. Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. J. Autoimmun. 57, 42&#x2013;52 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25554644</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2014.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers, S. A. et al. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus. Clin. Immunol. 185, 100&#x2013;108 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27570219</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2016.08.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers, S. A., Garcia, S. J., Reynolds, J. A., Herlitz, L. &amp; Putterman, C. NF-&#x3ba;B signaling in myeloid cells mediates the pathogenesis of immune-mediated nephritis. J. Autoimmun. 98, 33&#x2013;43 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30612857</ArticleId><ArticleId IdType="pmc">6426635</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2018.11.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, L. et al. Interleukin-22 from type 3 innate lymphoid cells aggravates lupus nephritis by promoting macrophage infiltration in lupus-prone mice. Front. Immunol. 12, 584414 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33717066</ArticleId><ArticleId IdType="pmc">7953152</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.584414</ArticleId></ArticleIdList></Reference><Reference><Citation>Arazi, A. et al. Immune cell heterogeneity in lupus nephritis kidneys and its relation to histopathological features [abstract]. Arthritis Rheumatol. 74 (suppl. 9), abstr 640 (2022).</Citation></Reference><Reference><Citation>Hoover, P. et al. Differentiation of injury-associated macrophages in lupus kidneys is conserved in humans and lupus mouse models [abstract]. Arthritis Rheumatol. 74, (suppl. 9), abstr 1666 (2022).</Citation></Reference><Reference><Citation>Kurts, C., Ginhoux, F. &amp; Panzer, U. Kidney dendritic cells: fundamental biology and functional roles in health and disease. Nat. Rev. Nephrol. 16, 391&#x2013;407 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32372062</ArticleId><ArticleId IdType="doi">10.1038/s41581-020-0272-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardowska, A., Komorniczak, M., Bullo-Piontecka, B., Debska-Slizien, M. A. &amp; Pikula, M. Transcriptomic and epigenetic alterations in dendritic cells correspond with chronic kidney disease in lupus nephritis. Front. Immunol. 10, 2026 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31507612</ArticleId><ArticleId IdType="pmc">6718474</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.02026</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci, M. et al. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 58, 251&#x2013;262 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18163476</ArticleId><ArticleId IdType="doi">10.1002/art.23186</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, X. et al. Renal-infiltrating CD11c<sup>+</sup> cells are pathogenic in murine lupus nephritis through promoting CD4<sup>+</sup> T cell responses. Clin. Exp. Immunol. 190, 187&#x2013;200 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28722110</ArticleId><ArticleId IdType="pmc">5629427</ArticleId><ArticleId IdType="doi">10.1111/cei.13017</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano, G. et al. Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. Mol. Immunol. 47, 2129&#x2013;2137 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20417969</ArticleId><ArticleId IdType="doi">10.1016/j.molimm.2010.02.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh, S. V. et al. A novel inflammatory dendritic cell that is abundant and contiguous to T cells in the kidneys of patients with lupus nephritis. Front. Immunol. 12, 621039 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33659005</ArticleId><ArticleId IdType="pmc">7919935</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.621039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, A. et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186, 1849&#x2013;1860 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21187439</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1001983</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorraji, E. S. et al. Kidney tertiary lymphoid structures in lupus nephritis develop into large interconnected networks and resemble lymph nodes in gene signature. Am. J. Pathol. 190, 2203&#x2013;2225 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32818496</ArticleId><ArticleId IdType="doi">10.1016/j.ajpath.2020.07.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaly, S., Rakaee, M., Abdi, R., Tsokos, G. C. &amp; Fenton, K. A. Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmun. Rev. 20, 102980 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34718163</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2021.102980</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz, O. M. et al. Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int. 74, 448&#x2013;457 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18528326</ArticleId><ArticleId IdType="doi">10.1038/ki.2008.191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa, T., Lee, Y. H., Sato, Y. &amp; Yanagita, M. Tertiary lymphoid tissues in kidney diseases: a perspective for the pediatric nephrologist. Pediatr. Nephrol. 38, 1399&#x2013;1409 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36251070</ArticleId><ArticleId IdType="doi">10.1007/s00467-022-05770-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, S. et al. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J. Immunol. 198, 2602&#x2013;2611 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28235864</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1600281</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorraji, S. E. et al. Mesenchymal stem cells and T cells in the formation of tertiary lymphoid structures in lupus nephritis. Sci. Rep. 8, 7861 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29777158</ArticleId><ArticleId IdType="pmc">5959845</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-26265-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava, R., Li, H. &amp; Tsokos, G. C. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr. Opin. Rheumatol. 35, 107&#x2013;116 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35797522</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000887</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava, R. &amp; Tsokos, G. C. The immune podocyte. Curr. Opin. Rheumatol. 31, 167&#x2013;174 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30562182</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakhi, H. et al. Podocyte injury in lupus nephritis. J. Clin. Med. 8, 1340 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31470591</ArticleId><ArticleId IdType="pmc">6780135</ArticleId><ArticleId IdType="doi">10.3390/jcm8091340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, R. D. &amp; Beresford, M. W. Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis. Am. J. Physiol. Renal Physiol. 315, F1683&#x2013;F1694 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30207171</ArticleId><ArticleId IdType="pmc">6336988</ArticleId><ArticleId IdType="doi">10.1152/ajprenal.00512.2017</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldwich, A. et al. Podocytes are nonhematopoietic professional antigen-presenting cells. J. Am. Soc. Nephrol. 24, 906&#x2013;916 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23539760</ArticleId><ArticleId IdType="pmc">3665387</ArticleId><ArticleId IdType="doi">10.1681/ASN.2012020133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Yu, F., Song, D., Wang, S. X. &amp; Zhao, M. H. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology 53, 1235&#x2013;1244 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24599917</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/ket491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezende, G. M. et al. Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria? Lupus 23, 255&#x2013;262 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24356611</ArticleId><ArticleId IdType="doi">10.1177/0961203313517152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruschi, M. et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J. Am. Soc. Nephrol. 26, 1905&#x2013;1924 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25398787</ArticleId><ArticleId IdType="doi">10.1681/ASN.2014050493</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, R. et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 69, 1636&#x2013;1646 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28544564</ArticleId><ArticleId IdType="pmc">5568813</ArticleId><ArticleId IdType="doi">10.1002/art.40155</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda, K. et al. CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. J. Clin. Invest. 128, 3445&#x2013;3459 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29985166</ArticleId><ArticleId IdType="pmc">6063476</ArticleId><ArticleId IdType="doi">10.1172/JCI99507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowling, T. K. Mesangial cells in lupus nephritis. Curr. Rheumatol. Rep. 23, 83 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34985599</ArticleId><ArticleId IdType="doi">10.1007/s11926-021-01048-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, H. et al. Mesangial cells exhibit features of antigen-presenting cells and activate CD4<sup>+</sup> T cell responses. J. Immunol. Res. 2019, 2121849 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31317046</ArticleId><ArticleId IdType="pmc">6604415</ArticleId><ArticleId IdType="doi">10.1155/2019/2121849</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, X. et al. MicroRNA-130b ameliorates murine lupus nephritis through targeting the type I interferon pathway on renal mesangial cells. Arthritis Rheumatol. 68, 2232&#x2013;2243 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27111096</ArticleId><ArticleId IdType="doi">10.1002/art.39725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinose, K. et al. Cutting edge: calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J. Immunol. 187, 5500&#x2013;5504 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22031763</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1102357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti, A. P., Bhargava, R., Dahan, S., Tsokos, M. G. &amp; Tsokos, G. C. Calcium/calmodulin kinase IV controls the function of both T cells and kidney resident cells. Front. Immunol. 9, 2113 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30333818</ArticleId><ArticleId IdType="pmc">6176098</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.02113</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, S., Healy, H. &amp; Kassianos, A. J. The emerging role of renal tubular epithelial cells in the immunological pathophysiology of lupus nephritis. Front. Immunol. 11, 578952 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33072122</ArticleId><ArticleId IdType="pmc">7538705</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.578952</ArticleId></ArticleIdList></Reference><Reference><Citation>Breda PC, W. T. et al. Renal proximal tubular epithelial cells exert immunomodulatory function by driving inflammatory CD4<sup>+</sup> T cell responses. Am. J. Physiol. Renal Physiol. 317, F77&#x2013;F89 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31017008</ArticleId><ArticleId IdType="doi">10.1152/ajprenal.00427.2018</ArticleId></ArticleIdList></Reference><Reference><Citation>Linke, A. et al. Antigen cross-presentation by murine proximal tubular epithelial cells induces cytotoxic and inflammatory CD8<sup>+</sup> T cells. Cells 11, 1510 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35563816</ArticleId><ArticleId IdType="pmc">9104549</ArticleId><ArticleId IdType="doi">10.3390/cells11091510</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, T. M. et al. IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. J. Clin. Invest. 131, e142428 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33956666</ArticleId><ArticleId IdType="pmc">8203450</ArticleId><ArticleId IdType="doi">10.1172/JCI142428</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset, F. &amp; Arnaud, L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun. Rev. 17, 44&#x2013;52 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29108825</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2017.11.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustelin, T., Lood, C. &amp; Giltiay, N. V. Sources of pathogenic nucleic acids in systemic lupus erythematosus. Front. Immunol. 10, 1028 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31139185</ArticleId><ArticleId IdType="pmc">6519310</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01028</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C, R. Q. et al. Increased risk of progression to lupus nephritis for lupus patients with elevated interferon signature [abstract]. Arthritis Rheumatol. 71 abstr 1914 (2019).</Citation></Reference><Reference><Citation>Crow, M. K., Olferiev, M. &amp; Kirou, K. A. Targeting of type I interferon in systemic autoimmune diseases. Transl. Res. 165, 296&#x2013;305 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25468480</ArticleId><ArticleId IdType="doi">10.1016/j.trsl.2014.10.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto, T. et al. High systemic type I interferon activity is associated with active class III/IV lupus nephritis. J. Rheumatol. 49, 388&#x2013;397 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34782453</ArticleId><ArticleId IdType="doi">10.3899/jrheum.210391</ArticleId></ArticleIdList></Reference><Reference><Citation>Zickert, A. et al. Interferon (IFN)-&#x3bb; is a potential mediator in lupus nephritis. Lupus Sci. Med. 3, e000170 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27933198</ArticleId><ArticleId IdType="pmc">5133405</ArticleId><ArticleId IdType="doi">10.1136/lupus-2016-000170</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke, V. et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res. Ther. 21, 107 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31036046</ArticleId><ArticleId IdType="pmc">6489203</ArticleId><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke, V. et al. IFN-&#x3bb;1 with Th17 axis cytokines and IFN-&#x3b1; define different subsets in systemic lupus erythematosus (SLE). Arthritis Res. Ther. 19, 139 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28619037</ArticleId><ArticleId IdType="pmc">5471711</ArticleId><ArticleId IdType="doi">10.1186/s13075-017-1344-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras, A. et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat. Commun. 11, 6149 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33262343</ArticleId><ArticleId IdType="pmc">7708979</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-19918-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindau, D. et al. TLR9 independent interferon &#x3b1; production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann. Rheum. Dis. 73, 2199&#x2013;2207 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24013727</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2012-203041</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairhurst, A. M. et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J. Immunol. 183, 6831&#x2013;6838 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19864599</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.0900742</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano, G. et al. Local synthesis of interferon-&#x3b1; in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res. Ther. 17, 72 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25889472</ArticleId><ArticleId IdType="pmc">4389585</ArticleId><ArticleId IdType="doi">10.1186/s13075-015-0588-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian, K. C. et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-&#x3b1;) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 75, 196&#x2013;202 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26038091</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2014-206090</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamashta, M. et al. Sifalimumab, an anti-interferon-&#x3b1; monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 1909&#x2013;1916 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27009916</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2015-208562</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211&#x2013;221 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau, F. A. et al. IFN-&#x3b1; kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann. Rheum. Dis. 79, 347&#x2013;355 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31871140</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2019-216379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaichian, Y., Wallace, D. J. &amp; Weisman, M. H. A promising approach to targeting type 1 IFN in systemic lupus erythematosus. J. Clin. Invest. 129, 958&#x2013;961 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30776023</ArticleId><ArticleId IdType="pmc">6391084</ArticleId><ArticleId IdType="doi">10.1172/JCI127101</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J. Clin. Invest. 129, 1359&#x2013;1371 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30645203</ArticleId><ArticleId IdType="pmc">6391094</ArticleId><ArticleId IdType="doi">10.1172/JCI124466</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyuan, I. T., Tzeng, H. T. &amp; Chen, J. Y. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells 8, 963 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31450787</ArticleId><ArticleId IdType="pmc">6769759</ArticleId><ArticleId IdType="doi">10.3390/cells8090963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, Y. &amp; Tummala, R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod. Rheumatol. 31, 1&#x2013;12 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32814461</ArticleId><ArticleId IdType="doi">10.1080/14397595.2020.1812201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard, A. FDA approves AstraZeneca&#x2019;s anifrolumab for lupus. Nat. Rev. Drug Discov. 20, 658 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34363027</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne, D. et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 81, 496&#x2013;506 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35144924</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrat, F. J., Elkon, K. B. &amp; Fitzgerald, K. A. Importance of nucleic acid recognition in inflammation and autoimmunity. Annu. Rev. Med. 67, 323&#x2013;336 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26526766</ArticleId><ArticleId IdType="doi">10.1146/annurev-med-052814-023338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz, G., Lech, M. &amp; Anders, H. J. Toll-like receptor activation in the pathogenesis of lupus nephritis. Clin. Immunol. 185, 86&#x2013;94 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27423476</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2016.07.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsova K, M. P. &amp; Rubtsov, A. V. TLR7, IFN&#x3b3;, and T-bet: their roles in the development of ABCs in female-biased autoimmunity. Cell Immunol. 294, 80&#x2013;83 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25541140</ArticleId><ArticleId IdType="doi">10.1016/j.cellimm.2014.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, L. et al. Activation of toll-like receptor-7 exacerbates lupus nephritis by modulating regulatory T cells. Am. J. Nephrol. 40, 325&#x2013;344 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25341693</ArticleId><ArticleId IdType="doi">10.1159/000368204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth, J. R., Molano, I., Ruiz, P., Coutermarsh-Ott, S. &amp; Cunningham, M. A. TLR7 agonism accelerates disease and causes a fatal myeloproliferative disorder in NZM 2410 lupus mice. Front. Immunol. 10, 3054 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31998321</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.03054</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, G. J. et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349&#x2013;356 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35477763</ArticleId><ArticleId IdType="pmc">9095492</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04642-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, T. et al. High TLR7 expression drives the expansion of CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> transitional B cells and autoantibody production in SLE patients. Front. Immunol. 10, 1243 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31231380</ArticleId><ArticleId IdType="pmc">6559307</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01243</ArticleId></ArticleIdList></Reference><Reference><Citation>Souyris M, C. C. et al. TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. 3, eaap8855 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29374079</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.aap8855</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairhurst, A. M. et al. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur. J. Immunol. 38, 1971&#x2013;1978 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18521959</ArticleId><ArticleId IdType="pmc">2993003</ArticleId><ArticleId IdType="doi">10.1002/eji.200838138</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417&#x2013;428 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16973389</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2006.07.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gies, V. et al. Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. JCI Insight 3, e96795 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29515028</ArticleId><ArticleId IdType="pmc">5922279</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.96795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, S., Fitzgerald, K. A., Cancro, M. P. &amp; Marshak-Rothstein, A. Nucleic acid-sensing receptors: rheostats of autoimmunity and autoinflammation. J. Immunol. 195, 3507&#x2013;3512 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26432899</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1500964</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, S. W. et al. Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J. Immunol. 192, 4525&#x2013;4532 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24711620</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1400098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossaller, L. et al. TLR9 deficiency leads to accelerated renal disease and myeloid lineage abnormalities in pristane-induced murine lupus. J. Immunol. 197, 1044&#x2013;1053 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27354219</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1501943</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov AV, R. K., Kappler, J. W. &amp; Marrack, P. TLR7 drives accumulation of ABCs and autoantibody production in autoimmune-prone mice. Immunol. Res. 55, 210&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22945807</ArticleId><ArticleId IdType="pmc">3935605</ArticleId><ArticleId IdType="doi">10.1007/s12026-012-8365-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan, S. K., Singh, V. V., Rai, R., Rai, M. &amp; Rai, G. Distinct autoantibody profiles in systemic lupus erythematosus patients are selectively associated with TLR7 and TLR9 upregulation. J. Clin. Immunol. 33, 954&#x2013;964 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23564191</ArticleId><ArticleId IdType="doi">10.1007/s10875-013-9887-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyn-Cook, B. D. et al. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol. Immunol. 61, 38&#x2013;43 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24865418</ArticleId><ArticleId IdType="doi">10.1016/j.molimm.2014.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow, M. K. Autoimmunity: interferon &#x3b1; or &#x3b2;: which is the culprit in autoimmune disease? Nat. Rev. Rheumatol. 12, 439&#x2013;440 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27411904</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2016.117</ArticleId></ArticleIdList></Reference><Reference><Citation>Buskiewicz IA, M. T. et al. Reactive oxygen species induce virus-independent MAVS oligomerization in systemic lupus erythematosus. Sci. Signal. 9, ra115 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27899525</ArticleId><ArticleId IdType="pmc">5321043</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aaf1933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. Association of abnormal elevations in IFIT3 with overactive cyclic GMP-AMP synthase/stimulator of interferon genes signaling in human systemic lupus erythematosus monocytes. Arthritis Rheumatol. 70, 2036&#x2013;2045 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29806091</ArticleId><ArticleId IdType="doi">10.1002/art.40576</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao, W. H. et al. Prion-like aggregation of mitochondrial antiviral signaling protein in lupus patients is associated with increased levels of type I interferon. Arthritis Rheumatol. 68, 2697&#x2013;2707 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27110677</ArticleId><ArticleId IdType="pmc">5079845</ArticleId><ArticleId IdType="doi">10.1002/art.39733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, W. et al. Antiviral adaptor MAVS promotes murine lupus with a B cell autonomous role. Front. Immunol. 10, 2452 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31681326</ArticleId><ArticleId IdType="pmc">6805724</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.02452</ArticleId></ArticleIdList></Reference><Reference><Citation>An, J. et al. Expression of cyclic GMP-AMP synthase in patients with systemic lupus erythematosus. Arthritis Rheumatol. 69, 800&#x2013;807 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27863149</ArticleId><ArticleId IdType="doi">10.1002/art.40002</ArticleId></ArticleIdList></Reference><Reference><Citation>Konig, N. et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann. Rheum. Dis. 76, 468&#x2013;472 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27566796</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2016-209841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremiah, N. et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J. Clin. Invest. 124, 5516&#x2013;5520 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25401470</ArticleId><ArticleId IdType="pmc">4348945</ArticleId><ArticleId IdType="doi">10.1172/JCI79100</ArticleId></ArticleIdList></Reference><Reference><Citation>Decout, A., Katz, J. D., Venkatraman, S. &amp; Ablasser, A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548&#x2013;569 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33833439</ArticleId><ArticleId IdType="pmc">8029610</ArticleId><ArticleId IdType="doi">10.1038/s41577-021-00524-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Klarquist, J. et al. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J. Immunol. 193, 6124&#x2013;6134 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25385820</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1401869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, S. et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. Proc. Natl Acad. Sci. USA 112, E710&#x2013;E717 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25646421</ArticleId><ArticleId IdType="pmc">4343138</ArticleId><ArticleId IdType="doi">10.1073/pnas.1420217112</ArticleId></ArticleIdList></Reference><Reference><Citation>Motwani, M. et al. cGAS-STING Pathway does not promote autoimmunity in murine models of SLE. Front. Immunol. 12, 605930 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33854495</ArticleId><ArticleId IdType="pmc">8040952</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.605930</ArticleId></ArticleIdList></Reference><Reference><Citation>Skopelja-Gardner, S., An, J. &amp; Elkon, K. B. Role of the cGAS-STING pathway in systemic and organ-specific diseases. Nat. Rev. Nephrol. 18, 558&#x2013;572 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35732833</ArticleId><ArticleId IdType="pmc">9214686</ArticleId><ArticleId IdType="doi">10.1038/s41581-022-00589-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang, N. et al. cGAS-STING activation contributes to podocyte injury in diabetic kidney disease. iScience 25, 105145 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36176590</ArticleId><ArticleId IdType="pmc">9513272</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2022.105145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiu, W. H., Lin, M. &amp; Tang, S. C. Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int. Suppl. 4, 20&#x2013;25 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/kisup.2014.5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan C, A. S., Stanik, V. &amp; Datta, S. K. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177, 1367&#x2013;1381 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8478612</ArticleId><ArticleId IdType="doi">10.1084/jem.177.5.1367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovgren, T., Eloranta, M. L., Bave, U., Alm, G. V. &amp; Ronnblom, L. Induction of interferon-&#x3b1; production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861&#x2013;1872 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15188363</ArticleId><ArticleId IdType="doi">10.1002/art.20254</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobjeva, N. V. &amp; Chernyak, B. V. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry 85, 1178&#x2013;1190 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33202203</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen, O. E. &amp; Borregaard, N. Neutrophil extracellular traps &#x2014; the dark side of neutrophils. J. Clin. Invest. 126, 1612&#x2013;1620 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27135878</ArticleId><ArticleId IdType="pmc">4855925</ArticleId><ArticleId IdType="doi">10.1172/JCI84538</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21389264</ArticleId><ArticleId IdType="pmc">3143837</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3001201</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni, C. &amp; Reizis, B. Self-DNA at the epicenter of SLE: immunogenic forms, regulation, and effects. Front. Immunol. 10, 1601 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31354738</ArticleId><ArticleId IdType="pmc">6637313</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigerblad, G. &amp; Kaplan, M. J. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-022-00787-0 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00787-0</ArticleId><ArticleId IdType="pubmed">36257987</ArticleId><ArticleId IdType="pmc">9579530</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakis, S. et al. NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-&#x3b1; production in patients with SLE. JCI Insight 6, e147671 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34554930</ArticleId><ArticleId IdType="pmc">8663547</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.147671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, D., Chen, X., Kang, R. &amp; Kroemer, G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 31, 107&#x2013;125 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33268902</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-00441-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, P. et al. Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. Nat. Immunol. 22, 1107&#x2013;1117 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34385713</ArticleId><ArticleId IdType="pmc">8609402</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-00993-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Alli, A. A. et al. Kidney tubular epithelial cell ferroptosis links glomerular injury to tubulointerstitial pathology in lupus nephritis. Clin. Immunol. 248, 109213 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36566913</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2022.109213</ArticleId></ArticleIdList></Reference><Reference><Citation>Linge, P., Fortin, P. R., Lood, C., Bengtsson, A. A. &amp; Boilard, E. The non-haemostatic role of platelets in systemic lupus erythematosus. Nat. Rev. Rheumatol. 14, 195&#x2013;213 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29559714</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2018.38</ArticleId></ArticleIdList></Reference><Reference><Citation>Melki I, A. I. et al. Platelets release mitochondrial antigens in systemic lupus erythematosus. Sci. Transl. Med. 13, eaav5928 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33597264</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aav5928</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli, S. et al. Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. Cell 184, 4464&#x2013;4479 e4419 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34384544</ArticleId><ArticleId IdType="pmc">8380737</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.07.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangou, E., Vassilopoulos, D., Boletis, J. &amp; Boumpas, D. T. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment. Autoimmun. Rev. 18, 751&#x2013;760 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31181324</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2019.06.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood, C. et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 22, 146&#x2013;153 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26779811</ArticleId><ArticleId IdType="pmc">4742415</ArticleId><ArticleId IdType="doi">10.1038/nm.4027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H., Li, T., Chen, S., Gu, Y. &amp; Ye, S. Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheumatol. 67, 3190&#x2013;3200 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26245802</ArticleId><ArticleId IdType="doi">10.1002/art.39296</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco, L. P. et al. Improved mitochondrial metabolism and reduced inflammation following attenuation of murine lupus with coenzyme Q10 analog idebenone. Arthritis Rheumatol. 72, 454&#x2013;464 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31566908</ArticleId><ArticleId IdType="pmc">7050361</ArticleId><ArticleId IdType="doi">10.1002/art.41128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science 366, 1531&#x2013;1536 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31857488</ArticleId><ArticleId IdType="pmc">8325171</ArticleId><ArticleId IdType="doi">10.1126/science.aav4011</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin, P. R. et al. Distinct subtypes of microparticle-containing immune complexes are associated with disease activity, damage, and carotid intima-media thickness in systemic lupus erythematosus. J. Rheumatol. 43, 2019&#x2013;2025 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27585687</ArticleId><ArticleId IdType="doi">10.3899/jrheum.160050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez, P., Rodriguez-Carrio, J., Martinez-Zapico, A., Caminal-Montero, L. &amp; Suarez, A. Circulating microparticle subpopulations in systemic lupus erythematosus are affected by disease activity. Int. J. Cardiol. 236, 138&#x2013;144 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28279502</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2017.02.107</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieker, J. et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol. 68, 462&#x2013;472 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26360137</ArticleId><ArticleId IdType="doi">10.1002/art.39417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobarrez, F. et al. Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. Sci. Rep. 6, 36025 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27777414</ArticleId><ArticleId IdType="pmc">5078765</ArticleId><ArticleId IdType="doi">10.1038/srep36025</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen, C. T., Ostergaard, O., Johnsen, C., Jacobsen, S. &amp; Heegaard, N. H. Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum. 63, 3067&#x2013;3077 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21702008</ArticleId><ArticleId IdType="doi">10.1002/art.30499</ArticleId></ArticleIdList></Reference><Reference><Citation>Rother, N., Pieterse, E., Lubbers, J., Hilbrands, L. &amp; van der Vlag, J. Acetylated histones in apoptotic microparticles drive the formation of neutrophil extracellular traps in active lupus nephritis. Front. Immunol. 8, 1136 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28959262</ArticleId><ArticleId IdType="pmc">5604071</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2017.01136</ArticleId></ArticleIdList></Reference><Reference><Citation>Arneth, B. Systemic lupus erythematosus and DNA degradation and elimination defects. Front. Immunol. 10, 1697 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31440232</ArticleId><ArticleId IdType="pmc">6692764</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01697</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler, J. et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res. Ther. 15, R84 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23945056</ArticleId><ArticleId IdType="pmc">3978901</ArticleId><ArticleId IdType="doi">10.1186/ar4264</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteith, A. J. et al. Defects in lysosomal maturation facilitate the activation of innate sensors in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 113, E2142&#x2013;E2151 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27035940</ArticleId><ArticleId IdType="pmc">4839468</ArticleId><ArticleId IdType="doi">10.1073/pnas.1513943113</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. et al. Cathepsin K deficiency ameliorates systemic lupus erythematosus-like manifestations in Fas<sup>lpr</sup> mice. J. Immunol. 198, 1846&#x2013;1854 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28093526</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1501145</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonam, S. R., Wang, F. &amp; Muller, S. Lysosomes as a therapeutic target. Nat. Rev. Drug Discov. 18, 923&#x2013;948 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31477883</ArticleId><ArticleId IdType="pmc">7097195</ArticleId><ArticleId IdType="doi">10.1038/s41573-019-0036-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisirak, V. et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell 166, 88&#x2013;101 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27293190</ArticleId><ArticleId IdType="pmc">5030815</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.05.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni, C. et al. Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA. Immunity 52, 1022&#x2013;1038.e1027 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32454024</ArticleId><ArticleId IdType="pmc">7306002</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2020.04.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. &amp; Xia, Y. Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies. Front. Immunol. 10, 1667 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31379858</ArticleId><ArticleId IdType="pmc">6650533</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01667</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky, D. S., Garza Reyna, A., Belina, M. E. &amp; Spencer, D. M. The interaction of anti-DNA antibodies with DNA: evidence for unconventional binding mechanisms. Int. J. Mol. Sci. 23, 5227 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35563617</ArticleId><ArticleId IdType="pmc">9105193</ArticleId><ArticleId IdType="doi">10.3390/ijms23095227</ArticleId></ArticleIdList></Reference><Reference><Citation>Rekvig, O. P. The anti-DNA antibodies: their specificities for unique DNA structures and their unresolved clinical impact &#x2014; a system criticism and a hypothesis. Front. Immunol. 12, 808008 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">35087528</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.808008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky, D. S. &amp; Lipsky, P. E. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 16, 565&#x2013;579 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32884126</ArticleId><ArticleId IdType="pmc">8456518</ArticleId><ArticleId IdType="doi">10.1038/s41584-020-0480-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Putterman, C. New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun. Rev. 3, 7&#x2013;11 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15003182</ArticleId><ArticleId IdType="doi">10.1016/S1568-9972(03)00082-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, Y., Janda, A., Eryilmaz, E., Casadevall, A. &amp; Putterman, C. The constant region affects antigen binding of antibodies to DNA by altering secondary structure. Mol. Immunol. 56, 28&#x2013;37 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23665381</ArticleId><ArticleId IdType="pmc">3687031</ArticleId><ArticleId IdType="doi">10.1016/j.molimm.2013.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, Y., Eryilmaz, E., Zhang, Q., Cowburn, D. &amp; Putterman, C. Anti-DNA antibody mediated catalysis is isotype dependent. Mol. Immunol. 69, 33&#x2013;43 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26655427</ArticleId><ArticleId IdType="doi">10.1016/j.molimm.2015.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Deocharan B, Q. X., Beger, E. &amp; Putterman, C. Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies. Lupus 11, 865&#x2013;871 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12529052</ArticleId><ArticleId IdType="doi">10.1191/0961203302lu308rr</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang, X. et al. Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity. Immun. Inflamm. Dis. 9, 407&#x2013;418 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33470559</ArticleId><ArticleId IdType="pmc">8127563</ArticleId><ArticleId IdType="doi">10.1002/iid3.401</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, M. Y., FitzPatrick, R. D., Buhler, K., Mahler, M. &amp; Fritzler, M. J. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun. Rev. 19, 102463 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31927088</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2020.102463</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumestre-Perard, C., Clavarino, G., Colliard, S., Cesbron, J. Y. &amp; Thielens, N. M. Antibodies targeting circulating protective molecules in lupus nephritis: interest as serological biomarkers. Autoimmun. Rev. 17, 890&#x2013;899 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30009962</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2018.03.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, M. J. et al. Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus. J. Autoimmun. 91, 1&#x2013;12 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29576246</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2018.02.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantarelli, C., Leventhal, J. &amp; Cravedi, P. Complement in lupus: biomarker, therapeutic target, or a little bit of both? Kidney Int. Rep. 6, 2031&#x2013;2032 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34386652</ArticleId><ArticleId IdType="pmc">8344109</ArticleId><ArticleId IdType="doi">10.1016/j.ekir.2021.06.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrisca, B., Sorohan, B., Tuta, L. &amp; Ismail, G. Advances in lupus nephritis pathogenesis: from bench to bedside. Int. J. Mol. Sci. 22, 3766 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33916456</ArticleId><ArticleId IdType="pmc">8038540</ArticleId><ArticleId IdType="doi">10.3390/ijms22073766</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyam, A., Hisada, R., Bhargava, R., Tsokos, M. G. &amp; Tsokos, G. C. Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. Transl. Res. 245, 18&#x2013;29 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35296451</ArticleId><ArticleId IdType="pmc">9167748</ArticleId><ArticleId IdType="doi">10.1016/j.trsl.2022.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Putterman, C. et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci. Med. 1, e000056 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25396070</ArticleId><ArticleId IdType="pmc">4225732</ArticleId><ArticleId IdType="doi">10.1136/lupus-2014-000056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, R. D., Bannerman, F., Beresford, M. W. &amp; Oni, L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol. 21, 245 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32605540</ArticleId><ArticleId IdType="pmc">7329551</ArticleId><ArticleId IdType="doi">10.1186/s12882-020-01888-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, A. Avacopan: first approval. Drugs 82, 79&#x2013;85 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01643-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, N. L., Birmingham, D. J. &amp; Rovin, B. H. Expanding the role of complement therapies: the case for lupus nephritis. J. Clin. Med. 10, 626 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33562189</ArticleId><ArticleId IdType="pmc">7915321</ArticleId><ArticleId IdType="doi">10.3390/jcm10040626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou, M., Pitsigavdaki, S. &amp; Bertsias, G. Lupus nephritis: improving treatment options. Drugs 82, 735&#x2013;748 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35486369</ArticleId><ArticleId IdType="doi">10.1007/s40265-022-01715-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap, D. Y. H. &amp; Mok, C. C. Novel and emerging treatment strategies for lupus nephritis. Expert. Rev. Clin. Pharmacol. 15, 1283&#x2013;1292 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36260817</ArticleId><ArticleId IdType="doi">10.1080/17512433.2022.2138340</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT05138133 (2021).</Citation></Reference><Reference><Citation>Zhao, Z. et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 179, 7949&#x2013;7958 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18025243</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.179.11.7949</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson, J. S., Wisniacki, N., Burkly, L. C. &amp; Putterman, C. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J. Autoimmun. 39, 130&#x2013;142 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22727560</ArticleId><ArticleId IdType="pmc">3428508</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2012.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, Y. et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin. Immunol. 145, 108&#x2013;121 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22982296</ArticleId><ArticleId IdType="pmc">3483377</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2012.08.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, Y. et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J. Am. Soc. Nephrol. 26, 1053&#x2013;1070 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25270074</ArticleId><ArticleId IdType="doi">10.1681/ASN.2014030233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias, R., Hasparyk, U. G., Lopes, M. P., de Barros, J. &amp; Simoes, E. S. A. C. Novel biomarkers for lupus nephritis in the &#x201c;OMICS&#x201d; era. Curr. Med. Chem. 28, 6011&#x2013;6044 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33583367</ArticleId><ArticleId IdType="doi">10.2174/0929867328666210212102438</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzo, L., Lindblom, J., Mohan, C. &amp; Parodis, I. Current insights on biomarkers in lupus nephritis: a systematic review of the literature. J. Clin. Med. 11, 5759 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36233628</ArticleId><ArticleId IdType="pmc">9570701</ArticleId><ArticleId IdType="doi">10.3390/jcm11195759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolouri, N. et al. Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus. Inflamm. Res. 71, 537&#x2013;554 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35298669</ArticleId><ArticleId IdType="doi">10.1007/s00011-022-01554-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin, M. et al. Prognostic and diagnostic values of novel serum and urine biomarkers in lupus nephritis: a systematic review. Am. J. Nephrol. 52, 559&#x2013;571 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34515043</ArticleId><ArticleId IdType="doi">10.1159/000517852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafouri-Fard, S., Shahir, M., Taheri, M. &amp; Salimi, A. A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. Cytokine 146, 155640 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34252872</ArticleId><ArticleId IdType="doi">10.1016/j.cyto.2021.155640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayry, A. et al. Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis. Lupus Sci. Med. 9, e000744 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36104119</ArticleId><ArticleId IdType="pmc">9476119</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000744</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold, T. B. et al. Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. Arthritis Res. Ther. 23, 132 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33931094</ArticleId><ArticleId IdType="pmc">8086067</ArticleId><ArticleId IdType="doi">10.1186/s13075-021-02511-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, S., Louis Sam Titus, A. S. C. &amp; Mohan, C. Elevated expression of receptors for EGF, PDGF, transferrin and folate within murine and human lupus nephritis kidneys. Clin. Immunol. 246, 109188 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36396012</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2022.109188</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, R. et al. A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Front. Immunol. 13, 1044743 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36569940</ArticleId><ArticleId IdType="pmc">9780296</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1044743</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, K., Liu, L., Zhang, X. &amp; Chen, X. An update on genetic susceptibility in lupus nephritis. Clin. Immunol. 210, 108272 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31683055</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2019.108272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Vizcaya, A. &amp; Isenberg, D. A. Clinical trials in systemic lupus erythematosus: the dilemma &#x2014; why have phase III trials failed to confirm the promising results of phase II trials? Ann. Rheum. Dis. 82, 169&#x2013;174 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36202589</ArticleId><ArticleId IdType="doi">10.1136/ard-2022-222839</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg, D. A. &amp; Merrill, J. T. Why, why, why de-lupus (does so badly in clinical trials). Expert. Rev. Clin. Immunol. 12, 95&#x2013;98 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26786849</ArticleId><ArticleId IdType="doi">10.1586/1744666X.2016.1112270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hruskova, Z. &amp; Tesar, V. Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert. Opin. Biol. Ther. 18, 989&#x2013;996 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30040494</ArticleId><ArticleId IdType="doi">10.1080/14712598.2018.1504918</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215&#x2013;1226 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22231479</ArticleId><ArticleId IdType="doi">10.1002/art.34359</ArticleId></ArticleIdList></Reference><Reference><Citation>Krustev, E., Clarke, A. E. &amp; Barber, M. R. W. B cell depletion and inhibition in systemic lupus erythematosus. Expert. Rev. Clin. Immunol. 19, 55&#x2013;70 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36342225</ArticleId><ArticleId IdType="doi">10.1080/1744666X.2023.2145281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124&#x2013;2132 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36109639</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>